Selected Grants
Mid-Atlantic praGmatic NETwork for Inclusive Clinical trials in emergency care (MAGNETIC)
ResearchCo Investigator · Awarded by National Institute of Neurological Disorders and Stroke · 2023 - 2028SOS-AMI
Clinical TrialCo Investigator · Awarded by Idorsia Pharmaceuticals Ltd · 2022 - 2026A multicenter,international,randomized,active comparator-controlled,double-blind,doubledummy, parallel-group,2-arm,Phase3 study to compare the efficacy and safety of the oral FXIa inhibitor asundexian(BAY 2433334) with apixaban for the prevention
Clinical TrialPrincipal Investigator · Awarded by Bayer Healthcare Pharmaceuticals Inc · 2023 - 2024CHANGE AFib
Clinical TrialCo Investigator · Awarded by American Heart Association · 2022 - 2024Participant Engagement And pReference study for cLinical outcomes associated with Atrial Fibrillation (Pearl-AF)
Clinical TrialPrincipal Investigator · Awarded by Bayer AG · 2022 - 2024A randomized controlled trial of rivaroxaban for the prevent of major cardiovascular events in patients with coronaryor periphery artery disease (COMPASS - Cardiovascular OutcoMes for People using Anticoagulation)
Clinical TrialPrincipal Investigator · Awarded by Bayer Healthcare Pharmaceuticals Inc · 2013 - 2020Prospective ARNI verses ACE inhibitor trial to determine superiority in reducing heart failure events after MI
Clinical TrialPrincipal Investigator · Awarded by Novartis Consumer Health, Inc. · 2016 - 2020Augustus
Clinical TrialPrincipal Investigator · Awarded by Bristol-Myers Squibb Company · 2017 - 2020A registry of high risk patients with coronary or peripheral artery disease
Clinical TrialPrincipal Investigator · Awarded by Hamilton Health Sciences Corporation · 2014 - 2015External Relationships
- Yale University
This faculty member (or a member of their immediate family) has reported outside activities with the companies, institutions, or organizations listed above. This information is available to institutional leadership and, when appropriate, management plans are in place to address potential conflicts of interest.